Geneva, March 23 -- International Clinical Trials Registry received information related to the study (KCT0011675) titled 'A Phase 1/2, Multicenter Clinical Trial Evaluating Golcamide, Poseltinib, and Rituximab in Patients with Relapsed/Refractory Large B-Cell Lymphoma' on March 4.
Study Type: Interventional Study
Study Design:
Primary Purpose : Treatment, Intervention Model : Single Group, Blinding/Masking : Open, Allocation : Not Applicable
Primary Sponsor: Seoul National University Hospital
Condition:
Neoplasms
Intervention:
Drug : Golcamide 0.4 mg is administered once daily for 14 consecutive days over 18 cycles, each cycle lasting 28 days. Rituximab is administered intravenously once daily at a dose of 375 mg/m² on days ...